Inactive Instrument

All News Resaphene Suisse AG

Equities

Resaphene Suisse AG: FDA Approval Process for Tinnitus Therapy Tinniwell Continues	22-07-13	CI
Resaphene Suisse AG: Tinnitus: 4 phases until healing in the Tailor-Made Notched Music Training (TMNMT) discovered with tinniwell	20-05-18	EQ
Resaphene Suisse AG Provides Update on Tinnitus: 4 Phases Until Healing in the Tailor-Made Notched Music Training Discovered with Tinniwell	20-05-18	CI
Resaphene Suisse AG: Correction of the ad hoc announcement dated March 30, 2020 Resaphene Suisse AG has announced the withdrawal of inclusion in the Vienna MTF at the Vienna Stock Exchange	20-03-31	EQ
Resaphene Suisse AG: Resaphene Suisse AG has applied for delisting at the Vienna Stock Exchange	20-03-30	EQ
Resaphene Suisse AG: Charité Ethics Committee in Berlin Approves Study on Tinniwell Tinnitus Therapy	20-01-21	BU
Resaphene Suisse AG: Charité Ethics Committee in Berlin approves study on tinniwell tinnitus therapy	20-01-21	EQ
Resaphene Suisse AG Announces Charité Ethics Committee in Berlin Approves Study on Tinniwell Tinnitus Therapy	20-01-21	CI
Resaphene Suisse AG: Breakthrough in Tinnitus Therapy	18-08-13	BU

No results for this search